18 results
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
20 Oct 23
Entry into a Material Definitive Agreement
5:00pm
, AS EXPRESSLY SET FORTH THEREIN) and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
6 Oct 21
Entry into a Material Definitive Agreement
4:22pm
, AS TO ANY OTHER NOTE DOCUMENT, AS EXPRESSLY SET FORTH THEREIN) and any claims, controversy, dispute or cause of action (whether in contract or tort
8-K
EX-2.1
RVLPQ
RVL Pharmaceuticals plc
30 Jun 21
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
6:04am
in the Seller Disclosure Schedule in any dispute or controversy between the Parties as to whether any obligation, item or matter not described
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
30 Jun 21
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
6:04am
; Consent to Service of Process.
(a) THIS AGREEMENT, INCLUDING THE AMENDMENT, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED
DRS/A
EX-10.1
d2a98o8najs
13 Jul 18
Draft registration statement (amended)
12:00am
DRS/A
EX-10.7
pc5ab
13 Jul 18
Draft registration statement (amended)
12:00am
DRS/A
EX-10.31
mu76we
20 Jun 18
Draft registration statement (amended)
12:00am
DRS/A
EX-10.32
wqfhcmk4
20 Jun 18
Draft registration statement (amended)
12:00am
DRS
EX-10.21
stwneq 19d
9 May 18
Draft registration statement
12:00am
DRS
EX-10.23
2d2h iu8tt
9 May 18
Draft registration statement
12:00am
DRS
EX-10.22
numnmkp
9 May 18
Draft registration statement
12:00am
DRS
EX-10.1
8iwsc8adx2q20e2
9 May 18
Draft registration statement
12:00am
DRS
EX-10.7
nlgj7q
9 May 18
Draft registration statement
12:00am
DRS
EX-10.20
kibckk
9 May 18
Draft registration statement
12:00am
- Prev
- 1
- Next